GLAXF - Alector: Potential In Neurology And Cancer Treatments
- Results from the phase 3 INFRONT-3 study using AL001 for the treatment of patients with Frontotemporal dementia are expected in 2023.
- Alector holds the potential to advance AL001 for both FTD-GRN and FTD-C9orf72 patients, plus several other neurological indications like Alzheimer's Disease and Parkinson's Disease.
- Alector has already established a partnership for the use of AL001 in neurodegenerative diseases with GSK. Already received an upfront payment of about $200 million from this partnership.
- Alector had $868.6 million in cash as of March 31, 2022. Enough cash to fund its operations into mid-2024.
For further details see:
Alector: Potential In Neurology And Cancer Treatments